We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+12.14%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$377M
AUM Growth
+$29.4M
Cap. Flow
+$9.81M
Cap. Flow %
2.6%
Top 10 Hldgs %
73.32%
Holding
28
New
2
Increased
4
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$12.4M
2
MRUS
Merus
MRUS
+$12.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$5.5M
4
PHVS icon
Pharvaris
PHVS
+$4.25M
5
VRDN icon
Viridian Therapeutics
VRDN
+$2.79M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$13.7M
2
IRON icon
Disc Medicine
IRON
+$7.38M
3
ARVN icon
Arvinas
ARVN
+$6.28M
4
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
+$1.24M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$545K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
1
Enliven Therapeutics
ELVN
$4.15B
$71.4M 18.95%
5,160,975
– –
TRDA icon
2
Entrada Therapeutics
TRDA
$282M
$66.5M 17.65%
4,408,379
– –
PHVS icon
3
Pharvaris
PHVS
$2.25B
$22.4M 5.93%
797,600
+210,000
+36% +$4.25M
CLDX icon
4
Celldex Therapeutics
CLDX
$2.96B
$19.7M 5.23%
497,270
+187,000
+60% +$5.5M
MLTX icon
5
MoonLake Immunotherapeutics
MLTX
$1.48B
$18.3M 4.85%
302,630
-10,580
-3% -$545K
BHVN icon
6
Biohaven
BHVN
$2.01B
$17.1M 4.54%
+399,972
New +$12.4M
IRON icon
7
Disc Medicine
IRON
$2.93B
$17M 4.51%
294,221
-144,221
-33% -$7.38M
DNTH icon
8
Dianthus Therapeutics
DNTH
$5.8B
$15.3M 4.06%
1,472,264
– –
MRUS
9
DELISTED
Merus
MRUS
$14.3M 3.8%
+521,531
New +$12.2M
VOR icon
10
Vor Biopharma
VOR
$1.16B
$14.3M 3.8%
318,086
– –
VRDN icon
11
Viridian Therapeutics
VRDN
$2.13B
$12.8M 3.39%
586,595
+176,595
+43% +$2.79M
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.3M 3%
192,500
– –
VKTX icon
13
Viking Therapeutics
VKTX
$3.8B
$10.9M 2.89%
585,000
– –
RLYB icon
14
Rallybio
RLYB
$84.6M
$8.68M 2.3%
453,841
– –
TYRA icon
15
Tyra Biosciences
TYRA
$1.91B
$7.69M 2.04%
554,979
+143,529
+35% +$1.86M
ANAB icon
16
AnaptysBio
ANAB
$1.59B
$7.66M 2.03%
357,733
– –
SCPH
17
DELISTED
scPharmaceuticals
SCPH
$7.53M 2%
1,200,647
– –
ZNTL icon
18
Zentalis Pharmaceuticals
ZNTL
$331M
$7.42M 1.97%
490,000
– –
SPRB
19
Spruce Biosciences
SPRB
$119M
$6.93M 1.84%
31,520
– –
RNAM
20
DELISTED
Avidity Biosciences
RNAM
$6.02M 1.6%
665,555
– –
COGT icon
21
Cogent Biosciences
COGT
$6.64B
$4.65M 1.23%
790,440
– –
MRSN
22
DELISTED
Mersana Therapeutics
MRSN
$3.03M 0.8%
52,200
– –
QTTB icon
23
Q32 Bio
QTTB
$450M
$2.76M 0.73%
251,996
– –
GHRS icon
24
GH Research
GHRS
$1.93B
$2.35M 0.62%
404,404
– –
CDTX
25
DELISTED
Cidara Therapeutics
CDTX
$901K 0.24%
56,726
– –
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q4 2023 Portfolio in Review

As of Q4 2023, 5AM Venture Management held 28 positions worth $377M, up 8.5% from $348M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

5AM Venture Management's Q4 2023 filing shows 2 new, 4 increased, 2 reduced and 3 closed positions. Its largest new stake was Biohaven: 399,972 shares worth $17.1M. The largest sale was Crinetics Pharmaceuticals, an estimated $13.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's largest Q4 2023 buy was Biohaven: 399,972 shares worth $17.1M.
  • 5AM Venture Management added most to Celldex Therapeutics in Q4 2023, an estimated $5.5M increase.
  • 5AM Venture Management's biggest Q4 2023 reduction was Disc Medicine, cutting an estimated $7.38M.
  • 5AM Venture Management fully exited Crinetics Pharmaceuticals in Q4 2023, selling an estimated $13.7M.
  • 5AM Venture Management's ten largest holdings make up 73% of its $377M portfolio in Q4 2023.
  • 5AM Venture Management opened 2 new positions and closed 3 in Q4 2023.
  • 5AM Venture Management's portfolio value rose 8.5% quarter-over-quarter to $377M.

Based on 5AM Venture Management's 13F filing for Q4 2023, filed 14 Feb 2024.